PT807125E - Anticorpos monoclonais anti-cd6 para o tratamento e diagnose da psoriase - Google Patents

Anticorpos monoclonais anti-cd6 para o tratamento e diagnose da psoriase

Info

Publication number
PT807125E
PT807125E PT96939805T PT96939805T PT807125E PT 807125 E PT807125 E PT 807125E PT 96939805 T PT96939805 T PT 96939805T PT 96939805 T PT96939805 T PT 96939805T PT 807125 E PT807125 E PT 807125E
Authority
PT
Portugal
Prior art keywords
psoriasis
monoclonal antibodies
diagnosis
treatment
clinical
Prior art date
Application number
PT96939805T
Other languages
English (en)
Portuguese (pt)
Inventor
Montero Casimiro Jose Enrique
Lombardero Valladares Josefa
Perez Rodriguez Rolando
Sierra Blazquez Patricia
Tormo Bravo Blanca Rosa
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of PT807125E publication Critical patent/PT807125E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT96939805T 1995-11-17 1996-11-18 Anticorpos monoclonais anti-cd6 para o tratamento e diagnose da psoriase PT807125E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis

Publications (1)

Publication Number Publication Date
PT807125E true PT807125E (pt) 2005-03-31

Family

ID=5459401

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96939805T PT807125E (pt) 1995-11-17 1996-11-18 Anticorpos monoclonais anti-cd6 para o tratamento e diagnose da psoriase

Country Status (15)

Country Link
US (1) US6572857B1 (2)
EP (1) EP0807125B1 (2)
JP (1) JP4113929B2 (2)
KR (1) KR100533854B1 (2)
CN (1) CN1222540C (2)
AT (1) ATE280783T1 (2)
AU (1) AU722882B2 (2)
BR (1) BRPI9607171B1 (2)
CA (1) CA2210751C (2)
CU (1) CU22584A1 (2)
DE (1) DE69633717T2 (2)
DK (1) DK0807125T3 (2)
ES (1) ES2231826T3 (2)
PT (1) PT807125E (2)
WO (1) WO1997019111A2 (2)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534022A (ja) * 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
CU23097A1 (es) 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
US20070003568A1 (en) 2003-02-24 2007-01-04 Alice Dautry-Varsat Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof
PT2119452T (pt) * 2006-12-26 2020-05-08 Ct Inmunologia Molecular Composição farmacêutica que compreende um anticorpo monoclonal anti-cd6 utilizado no diagnóstico e tratamento de artrite reumatoide
KR101482959B1 (ko) 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
JP5511684B2 (ja) 2008-01-11 2014-06-04 アドヘロン セラピューティクス，インコーポレイテッド 炎症性関節障害を治療するためのカドヘリン−１１ｅｃｌドメインアンタゴニスト
EA201001467A1 (ru) * 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
US8940300B2 (en) * 2010-07-15 2015-01-27 Adheron Therapeutics, Inc. Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9910039B2 (en) 2011-07-01 2018-03-06 Beckman Coulter, Inc. Regulatory T cells and methods of identifying, obtaining and using to treat immuno-based disorders
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
FR3000216B1 (fr) * 2012-12-21 2015-02-06 Galderma Res & Dev Utilisation de proteases particulieres pour la detection de trichophytons et de pathologies associees
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2920368C (en) 2013-07-23 2023-03-21 Centro De Inmunologia Molecular Use of a cd6 binding partner and method based thereon
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
CN105504062B (zh) * 2015-12-25 2019-06-04 百泰生物药业有限公司 一种抗CD6单抗T1h的检测性抗体及应用
PL3529274T3 (pl) 2016-10-21 2024-09-09 Biocon Limited Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
SG11202008149RA (en) 2018-02-27 2020-09-29 Equillium Inc Anti cd6 antibodies for treating severe asthma
US12281151B2 (en) 2018-06-29 2025-04-22 City Of Hope CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
MX2021010283A (es) 2019-02-26 2021-09-30 Equillium Inc Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.
WO2021138454A1 (en) 2019-12-30 2021-07-08 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
JP2024534975A (ja) 2021-09-08 2024-09-26 セントロ ド インムノロジア モレキュラー 過剰炎症反応に起因する細胞および臓器の損傷の予防における抗ｃｄ６モノクローナル抗体の使用
WO2025096685A1 (en) 2023-10-30 2025-05-08 City Of Hope Methods of making and using regulatory t cells for treatment of autoimmune disorders and cancers
CN120005027B (zh) * 2025-04-10 2025-09-23 中国水产科学研究院长江水产研究所 大口黑鲈cd6抗原结合肽、及其单克隆抗体和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2175247A1 (en) * 1993-11-02 1995-05-11 Barton F. Haynes Cd6 ligand
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos

Also Published As

Publication number Publication date
CA2210751C (en) 2007-01-30
CN1175957A (zh) 1998-03-11
ES2231826T3 (es) 2005-05-16
EP0807125A2 (en) 1997-11-19
DK0807125T3 (da) 2005-03-14
AU7690596A (en) 1997-06-11
WO1997019111A2 (es) 1997-05-29
DE69633717D1 (de) 2004-12-02
CU22584A1 (es) 1999-11-03
WO1997019111A3 (es) 1998-02-12
US6572857B1 (en) 2003-06-03
BR9607171A (pt) 1997-11-11
KR19980701502A (ko) 1998-05-15
CN1222540C (zh) 2005-10-12
DE69633717T2 (de) 2006-02-02
JPH11506017A (ja) 1999-06-02
JP4113929B2 (ja) 2008-07-09
KR100533854B1 (ko) 2006-09-20
MX9705445A (es) 1998-06-30
CA2210751A1 (en) 1997-05-29
AU722882B2 (en) 2000-08-10
ATE280783T1 (de) 2004-11-15
EP0807125B1 (en) 2004-10-27
BRPI9607171B1 (pt) 2016-07-19

Similar Documents

Publication Publication Date Title
PT807125E (pt) Anticorpos monoclonais anti-cd6 para o tratamento e diagnose da psoriase
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
ES2084338T3 (es) Anticuerpos recombinantes especificos para el tnf alfa.
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
NO20092874L (no) Forhindring og behandling av amyloidogen sykdom
EA200101064A1 (ru) Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами
RU2008128244A (ru) Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2
BR9812846A (pt) Anticorpo humanizado natural
DE69922261D1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
DK0586002T3 (da) Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho
DE69529649D1 (de) Anti-egfr einkettige fvs und anti-egfr antikoerper
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
ATE85652T1 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
ATE266417T1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
FI950062A0 (fi) Proteiinien foroaktivaatio konjugaatiotarkoituksia varten
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
BR0210648A (pt) Variante de uma molécula imunointerativa, anticorpo monoclonal, forma disimunizada de anticorpo monoclonal 3b6, método para a geração de um anticorpo monoclonal desimunizado, molécula de anticorpo desimunizada, anticorpo desimunizado, anticorpo monoclonal de murino variante 3b6 desimunizado, variante de um anticorpo monoclonal de murino 3b6 desimunizado para uso em humanos, método para a detecção de um coágulo sanguìneo em um paciente humano, método para a detecção de um coágulo sanguìneo ou de um seu fragmento de ligação a antìgeno, método para a facilitação da dissolução ou da remoção de um coágulo sanguìneo em um humano, uso de um anticorpo monoclonal derivado de murino variante, e, conjugado
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
ATE407149T1 (de) Detoxifizierung durch intramuskulär verabreichte f(ab')2 fragmente
EP1532162A4 (en) HUMANIZED ANTI-DAY-72 CC49 FOR DIAGNOSIS AND THERAPY HUMAN TUMORS
FR2804027B1 (fr) Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
DK0588477T3 (da) Medicinsk præparat omfatende TCF-11